Serum Institute seeks indemnity from liability: sources
The Hindu
With Centre considering Pfizer, Moderna’s plea, firm hopes rules will be same for all
With the Centre favourably Pfizer and Moderna prior to their rollout in India, the Pune-based Serum Institute of India (SII) has also sought indemnity from liability, expressing the hope that rules would be the same for everyone, said sources on Thursday. As per company sources, the Adar Poonawalla-led SII, which manufactures Covishield (the Indian name for the AstraZeneca-Oxford jab) vaccine, has reportedly conveyed to the Centre that all vaccine makers, whether Indian or foreign, ought to be granted the same protection (against the cost of compensation in the event of cases of severe side-effects). “If foreign vaccine makers are given indemnity protection, then all vaccine firms in the country, not just the SII, must be given the same. We are hoping the same rules apply to everyone,” said an SII source.More Related News

Insurance penetration and density are often misunderstood and do not reveal how many families are insured or whether they would be financially secure if the main earning member were to die. The real issue is not reach but adequacy, as households may have life insurance but not enough cover to replace lost income, leaving them financially vulnerable.












